» Articles » PMID: 10899646

Prostate Cancer Screening: the Problem of Overdiagnosis and Lessons to Be Learned from Breast Cancer Screening

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2000 Jul 19
PMID 10899646
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Screening for prostate cancer is a relatively new procedure, still under experimental evaluation within prospective randomised trials. The design of prospective studies has been mainly based on the experience of other cancer screenings, particularly breast cancer, for which data of several controlled studies are available. Unfortunately, breast cancer is very different from prostate cancer, particularly for aspects such as early diagnosis and, thus the screening process, originally modelled on the basis of the lesson taught by breast cancer screening, needs continuous re-evaluation and adjustment, based on data which are now being produced from ongoing screening experiences. In this paper, we will consider the most controversial aspects of prostate cancer screening and compare prostate screening with breast cancer screening in order to promote a better understanding of the current problems and lessons to be learned.

Citing Articles

A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.

Wu H, Wu Y, He P, Liang J, Xu X, Ji C PLoS One. 2024; 19(2):e0285745.

PMID: 38329970 PMC: 10852267. DOI: 10.1371/journal.pone.0285745.


Four Novel Prognostic Genes Related to Prostate Cancer Identified Using Co-expression Structure Network Analysis.

Feng T, Wei D, Li Q, Yang X, Han Y, Luo Y Front Genet. 2021; 12:584164.

PMID: 33927744 PMC: 8078837. DOI: 10.3389/fgene.2021.584164.


Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis.

Song Z, Chao F, Zhuo Z, Ma Z, Li W, Chen G Aging (Albany NY). 2019; 11(13):4736-4756.

PMID: 31306099 PMC: 6660050. DOI: 10.18632/aging.102087.


In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.

Cava C, Bertoli G, Colaprico A, Bontempi G, Mauri G, Castiglioni I Int J Mol Sci. 2018; 19(3).

PMID: 29562723 PMC: 5877771. DOI: 10.3390/ijms19030910.


In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57.

Dam J, Olsen B, Baun C, Hoilund-Carlsen P, Thisgaard H Mol Imaging Biol. 2015; 18(3):368-76.

PMID: 26561028 DOI: 10.1007/s11307-015-0911-z.